Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Positive late-breaking news on a new pathway – Factor XIa inhibition – for antithrombotic treatment for stroke risk reduction
Secondary prevention trial in patients (>12,000 pts) after non-cardioembolic ischemic stroke or high-risk TIA
OCEANIC-STROKE demonstrates superiority of asundexian vs. Placebo (in both study arms in combo with antiplatelet therapy), showing significant reduction in ischemic stroke risk, without increasing bleeding risk
OCEANIC-STROKE is the first successfully completed Phase III study of a Factor XIa inhibitor (50 mg p.o. once daily)
Adding an antithrombotic agent (here: asundexian) to best medical treatment (here: antiplatelet treatment) with significant reduction in ischemic risk and – at the same time – without (!) increasing overall bleeding risk is highly remarkable!
Uncoupling thrombosis- and haemostasis risk”
Read the full article here.
Stay updated with Hemostasis Today.
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke